Is ADC Therapeutics SA (ADCT) a Stock to Watch After Gaining 26.76% This Week?

ADC Therapeutics SA (ADCT) stock is up 26.76% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator.

ADC Therapeutics SA has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on ADCT!

See Full ADCT Report

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company. Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive. InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend. Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With ADCT Stock Today?

ADC Therapeutics SA (ADCT) stock has risen 15.01% while the S&P 500 is lower by -0.07% as of 1:52 PM on Thursday, Nov 30. ADCT is higher by $0.12 from the previous closing price of $0.78 on volume of 823,967 shares. Over the past year the S&P 500 is up 14.90% while ADCT is lower by -73.37%. ADCT lost -$2.20 per share in the over the last 12 months. To see InvestorsObserver's Sentiment Score for ADC Therapeutics SA click here.

More About ADC Therapeutics SA

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212. Click Here to get the full Stock Report for ADC Therapeutics SA stock.